Clinical Trials for the Nonsecretory Myeloma Patient with Dr. Sascha Tuchman
Are there any clinical trials that are currently open for non-secretory patients? Why aren't they allowed to participate in the majority of clinical trials? Will clinical trial requirements change in the future so that they can start participating?
Audrey Burton-Bethke
Audrey joined the HealthTree Foundation as the Myeloma Community Program Director in 2020. While not knowing much about myeloma at the start, she has since worked hard to educate herself, empathize and learn from others' experiences. She loves this job. Audrey is passionate about serving others, loves learning, and enjoys a nice mug of hot chocolate no matter the weather.
Sascha Tuchman, MD
Dr. Tuchman is a board-certified medical oncologist and divides his time between clinical care and clinical research. He studies and treats all forms of plasma cell disorders but has a special research interest in amyloidosis, and in managing older, frail patients with multiple myeloma. He has years of experience in managing patients and leading research efforts in these disorders, and he directs the multiple myeloma and amyloidosis program at UNC. As part of that role, he mentors the research and career development of trainees who have an interest in myeloma and related conditions. Outside UNC, Dr. Tuchman sits on expert groups that design research in and formulate guidelines for managing plasma cell disorders, such as the International Myeloma Working Group, the International Society for Amyloidosis, and the multiple myeloma committee in the Alliance cooperative cancer research group. When not at work, he enjoys playing ice hockey, cycling, playing music, studying languages, reading history, and spending time with his family including his wife and three sons.